McKesson Reports Strong Q3 Results, Raises Full-Year Adjusted EPS Guidance

summarizeSummary

McKesson Corporation announced robust third-quarter results, with significant revenue and adjusted EPS growth, and subsequently raised its full-year adjusted earnings per diluted share guidance. The company also completed the divestiture of its European operations.

check_boxKey Events

• Strong Q3 Financial Performance

  McKesson reported third-quarter revenues of $106.2 billion, an 11% increase year-over-year, and adjusted earnings per diluted share of $9.34, up 16%.

• Raised Full-Year Guidance

  The company raised and narrowed its fiscal 2026 Adjusted Earnings per Diluted Share guidance range to $38.80 to $39.20, up from the previous range of $38.35 to $38.85, indicating continued growth.

• Completed European Divestiture

  McKesson finalized the sale of its Norwegian retail and distribution businesses on January 30, 2026, completing its exit from European operations and streamlining its global focus.

• Solid Cash Flow Generation

  The company generated $1.2 billion in cash flow from operations and $1.1 billion in Free Cash Flow during the quarter.

auto_awesomeAnalysis

McKesson's third-quarter performance demonstrates strong operational momentum, driven by increased prescription volumes and growth in specialty products. The 16% increase in adjusted earnings per diluted share and 11% revenue growth highlight the strength of its core distribution businesses. The decision to raise full-year adjusted EPS guidance signals management's confidence in continued performance and a positive outlook for the remainder of fiscal 2026. Furthermore, the completion of the European divestiture simplifies the company's operational footprint and fulfills a strategic commitment, allowing for greater focus on core North American businesses. Investors should view this report as a strong affirmation of McKesson's strategic execution and financial health.